Status:
COMPLETED
Dehydroepiandrosterone Maintain Mitochondrial Quality of Cumulus Cells in Poor Ovarian Responders
Lead Sponsor:
Kaohsiung Veterans General Hospital.
Conditions:
Poor Responders
Dehydroepiandrosterone
Eligibility:
FEMALE
25-45 years
Phase:
NA
Brief Summary
To investigate whether the DHEA supplementation could improve mitochondrial quality in poor ovarian responders
Detailed Description
Women who underwent in vitro fertilization (IVF) treatment participated, including normal ovarian responders (NORs) and poor ovarian responders (PORs). PORs were assigned to receive DHEA supplementati...
Eligibility Criteria
Inclusion
- Poor ovarian responders met the Bologna criteria, having at least two of the three following features: (1) advanced maternal age (≥ 40 years) or any other risk factor for POR, (2) a previous POR (≤ 3 oocytes with a conventional stimulation protocol), and (3) an abnormal ovarian reserve test. An abnormal ovarian reserve test was defined as antral follicle counts (AFC) \< 5 or anti-Müllerian hormone (AMH) \< 1 ng/mL in this study.
- Normal ovarian responders met the following criteria: (1) AFCs ≥ 5 or AMH ≥ 1 ng/mL and (2) the number of retrieved oocytes was between 5 and 15.
Exclusion
- previous oophorectomy
- exposure to cytotoxic or pelvic irradiation for malignancy
- positive screening for recurrent pregnancy loss (chromosome mapping, antinuclear antibodies, extractable nuclear antigens, antiphospholipid antibodies, thrombophilic screening)
- any other sensitizing or ovarian stimulating therapy during the previous 3 months
Key Trial Info
Start Date :
September 6 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2019
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT03438812
Start Date
September 6 2017
End Date
December 31 2019
Last Update
February 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaohsiung Veterans General Hospital
Kaohsiung City, Taiwan, 81362